Synthesis of 4-Hydroxycoumarin-Based Triazoles/Oxadiazoles as Novel Anticancer Agents
© 2022 Wiley-VHCA AG, Zurich, Switzerland..
A series of novel 3-substituted-4-hydroxycoumarins 7 and 8 containing (5-aryl-1,3,4-oxadiazol-2-yl)thio or (4-amino-5-aryl-4H-1,2,4-triazol-3-yl)thio moieties have been synthesized and evaluated as anticancer agents. The in vitro MTT assay of compounds against hepatocellular carcinoma (HepG2), breast cancer (MCF7) cells, and a human colorectal adenocarcinoma cell line with epithelial morphology (HT29) indicated that the HepG2 cells had more susceptibility to the tested compounds. Indeed, all compounds (with the exception of 7b, 7c, 7g, and 8g) were more potent than the standard drug doxorubicin against HepG2 cells (IC50 values=1.65-3.83 μM). Although, the better result was obtained with the oxadiazole analog 7h against HepG2 (IC50 =1.65 μM), the N-amino-triazole derivatives 8c, 8e, 8f and, 8h with IC50 values of 1.78-6.34 μM showed potent activity against all tested cell lines. The good drug-like properties and in vitro potency and selectivity of 4-hydroxycoumarins 8 make them as good leads for the development of new anticancer agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Chemistry & biodiversity - 19(2022), 10 vom: 07. Okt., Seite e202200043 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashemi, Seyedeh Mahdieh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4-Hydroxycoumarins |
|---|
| Anmerkungen: |
Date Completed 21.10.2022 Date Revised 21.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cbdv.202200043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346969484 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346969484 | ||
| 003 | DE-627 | ||
| 005 | 20231226032720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cbdv.202200043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346969484 | ||
| 035 | |a (NLM)36181443 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashemi, Seyedeh Mahdieh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis of 4-Hydroxycoumarin-Based Triazoles/Oxadiazoles as Novel Anticancer Agents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2022 | ||
| 500 | |a Date Revised 21.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley-VHCA AG, Zurich, Switzerland. | ||
| 520 | |a A series of novel 3-substituted-4-hydroxycoumarins 7 and 8 containing (5-aryl-1,3,4-oxadiazol-2-yl)thio or (4-amino-5-aryl-4H-1,2,4-triazol-3-yl)thio moieties have been synthesized and evaluated as anticancer agents. The in vitro MTT assay of compounds against hepatocellular carcinoma (HepG2), breast cancer (MCF7) cells, and a human colorectal adenocarcinoma cell line with epithelial morphology (HT29) indicated that the HepG2 cells had more susceptibility to the tested compounds. Indeed, all compounds (with the exception of 7b, 7c, 7g, and 8g) were more potent than the standard drug doxorubicin against HepG2 cells (IC50 values=1.65-3.83 μM). Although, the better result was obtained with the oxadiazole analog 7h against HepG2 (IC50 =1.65 μM), the N-amino-triazole derivatives 8c, 8e, 8f and, 8h with IC50 values of 1.78-6.34 μM showed potent activity against all tested cell lines. The good drug-like properties and in vitro potency and selectivity of 4-hydroxycoumarins 8 make them as good leads for the development of new anticancer agents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anticancer activity | |
| 650 | 4 | |a coumarin | |
| 650 | 4 | |a oxadiazole | |
| 650 | 4 | |a triazole | |
| 650 | 7 | |a Oxadiazoles |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a 4-Hydroxycoumarins |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 700 | 1 | |a Hosseini-Khah, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudi, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemistry & biodiversity |d 2004 |g 19(2022), 10 vom: 07. Okt., Seite e202200043 |w (DE-627)NLM167405101 |x 1612-1880 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:10 |g day:07 |g month:10 |g pages:e202200043 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cbdv.202200043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 10 |b 07 |c 10 |h e202200043 | ||